Home › Funds › Redmile Group, LLC › NGNE

Redmile Group, LLC position in NGNE

NEUROGENE INC COM · Health Care

Redmile Group, LLC reported holding 1,412,199 shares of NGNE (NEUROGENE INC COM) in its Q2 2026 13F filing — a position valued at US$44.4M, representing 2.98% of its reported portfolio and ranking #10 among its reported holdings. Redmile Group, LLC has disclosed NGNE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)1.41M sh
Reported value held$44.41M
Portfolio Weight2.98%
First reportedQ4 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Redmile Group, LLC's NGNE position evolved

Redmile Group, LLC first disclosed a stake in NGNE in Q4 2023 at 946,897 shares (US$18.4M). The position peaked in Q1 2024 at 935,252 shares, worth US$47.6M. Across 11 filings, Redmile Group, LLC increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,412,199 shares valued at US$44.4M — a reduction of -47,400 shares quarter over quarter.. Notable position changes include a 37% increase in Q4 2024 (shares fell 49% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 946.90K $18.35M New
Q1 2024 935.25K $47.60M Reduce
Q2 2024 1.01M $36.89M Add
Q3 2024 964.35K $40.46M Reduce
Q4 2024 1.32M $30.17M Add
Q1 2025 1.31M $15.32M Reduce
Q2 2025 1.28M $19.09M Reduce
Q3 2025 1.30M $22.51M Add
Q4 2025 1.46M $30.07M Add
Q1 2026 1.46M $29.43M Hold
Q2 2026 1.41M $44.41M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NGNE and 13F data

NGNE (NEUROGENE INC COM) is a Health Care company. 37 other funds we track also report a position in NGNE — the largest reported positions include Samsara BioCapital, LLC (US$54.0M), Casdin Capital (US$48.6M), RTW INVESTMENTS, LP (US$42.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NGNE

All NGNE fund holders →

FAQ

How long has Redmile Group, LLC held NGNE?

Redmile Group, LLC has disclosed NGNE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is Redmile Group, LLC's current position in NGNE?

As of Q2 2026, Redmile Group, LLC holds 1.41M shares of NGNE (NEUROGENE INC COM), valued at $44.41M, representing 2.98% of its reported portfolio and ranking #10.

Has Redmile Group, LLC been buying or selling NGNE?

In the latest 13F filing (Q2 2026), Redmile Group, LLC reduced its position in NGNE. The position peaked in Q1 2024 at 935.25K shares.

Which other funds hold NGNE?

Other major institutional holders of NGNE include Samsara BioCapital, LLC, Casdin Capital, RTW INVESTMENTS, LP, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.